| Selvita appoints Dr Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board |
|
Selvita Sp. z o.o. , a drug discovery company headquartered in Krakow, Poland, announced today the appointment of Dr. Nicolas D. Beuzen as its Chief Scientific Officer and Member of the Management Board. Dr. Beuzen will oversee all Selvita’s drug research projects. "Nicolas is a remarkable addition to our management team," stated Pawel Przewiezlikowski, Chief Executive Officer of Selvita. "His scientific and business education, as well as his experience with a big pharmaceutical company, a start-up and in outsourced drug development will provide an invaluable perspective for our future growth”. After the first experience in 2002 as a Strategic Database Manager at Sanofi Pasteur MSD, Dr Beuzen joined in 2003 OPi Pharmaceuticals (now EUSA) as Project Manager. His activities included work on pre-clinical onco-haematology drug candidates (monoclonal antibodies and small molecules) as well as stage II-IV development in onco-haematology, CNS and metabolism. In 2006 he moved to India as Project Coordinator at Ethypharm, where he managed an international cross-functional team on the ‘New Drug Delivery’ portfolio of the French company. He holds a PhD in Molecular Biology from the University of Glasgow (United Kingdom) , B.Sc. in Applied biology – biotechnology and protein engineering from London South Bank University (United Kingdom). He is also a graduate of Université Jean Moulin (Lyon III) in Lyons (France) where he obtained his DESS (eq. M.A.) degree in Marketing of pharmaceutical products. "Selvita has a strong target modelling and drug discovery platform, good lead generation capabilities, and an impressive scientific team of researchers and scientists," said Dr. Beuzen. "I look forward to contributing to the success of the company." About SelvitaSelvita is a private biotechnology company from Krakow, Poland. Its aim is to help global pharmaceutical and biotechnology companies to gain efficient access to innovative compounds developed at Polish universities and good research capabilities of Polish scientists. The company develops its own innovative compounds pipeline up to the IND stage, provides bioinformatics and chemical informatics services to the pharmaceutical industry as well as pre-clinical ADMET and biochemistry research services through its daughter company BioCentrum.Selvita specializes in:
More about Selvita: http://www.selvita.com Media contact: Selvita: Pawel Przewiezlikowski, CEO Tel: +48 12 410 73 80 e-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it |